Physician profile
Michael Stephen Kocinski
NPI 1295798262
$5,408.72
in general payments reported to CMS, 2019-2025
28 companies · $1,334 in 2025
The $1,334 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $311 · 2021: $626 · 2022: $738 · 2023: $822 · 2024: $1,343 · 2025: $1,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,498.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,537.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $789.66 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $506.36 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.82 | 2021-2025 | Jardiance |
| Abbott Laboratories | $206.46 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $204.36 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $194.33 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $178.18 | 2024-2025 | Trintellix |
| Glaxosmithkline, LLC. | $169.72 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $144.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $138.30 | 2020-2022 | |
| Abbvie INC. | $131.85 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $130.48 | 2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $129.22 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $111.28 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $82.91 | 2023-2025 | |
| Amarin Pharma, INC. | $72.53 | 2019-2021 | |
| Eisai INC. | $52.17 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.93 | 2024-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $38.60 | 2022 | |
| Biogen, INC. | $34.95 | 2022 | |
| Idorsia Pharmaceuticals US INC | $32.17 | 2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $26.97 | 2022-2023 | Edarbi |
| Arbor Pharmaceuticals, INC. | $25.48 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.41 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $14.76 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.23 | 2024 | Givlaari |
| Axonics, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kocinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.